Hemoabsorption in Acute-On-Chronic Liver Failure

Recruiting

• Conditions: K72; Hepatic failure, not elsewhere classified

• Registration Number: DRKS00033570
• Lead Sponsor: niklinik RWTH Aachen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

ACLF with intensive care treatment and ongoing renal replacement therapy through an indwelling catheter, and indication for absorbertherapy

Exclusion Criteria

Pregnancy
Acute Liver Failure

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemodynamic stabilization, as indicated by reduction of vasopressor dosage and MAP (mean arterial pressure) in patients receiving absorption therapy.

Secondary Outcome Measures

Name	Time	Method
- 30-day-and 60-day-mortality<br>- Length of stay (LOS) on ICU<br>- Indicators for stabilization of inflammatory conditions, such as white blood cell count, differential analyses of neutrophils and monocytes<br>- Serum CRP, PCT, IL6, IL10 and TNFa<br>- Serum bile acid concentrations<br>- Serum bilirubin concentrations<br>- Liver organ function, as indicated by INR and coagulation factor V<br>